Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 1-6

  Rogers, S L ^a   Friedhoff, L T ^a  

^a EISAI INC   (United States)

Author keywords

Alzheimer's disease; Donepezil; Pharmacodynamics; Pharmacokinetics; Selective acetylcholinesterase inhibitor

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; ENZYME INHIBITION; ERYTHROCYTE MEMBRANE; FATIGUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIOENZYMATIC ASSAY; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; VOMITING;

EID: 0032424680     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1001.x     Document Type: Article

References (22)

1. Whitehouse PJ, Price DL, Clarke AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucelus basalis. Ann Neurol 1981; 10: 122-126.
2. Giacobini E. Pharmacotherapy of Alzheimer's disease: new drugs and novel strategies. Prog Brain Res 1993; 98: 447-454.
3. Davis RE, Doyle PD, Carroll RT, Emmerling MR, Jaen J. Cholinergic therapies for Alzheimer's disease. Arzneimittelforschung 1995; 45: 425-431.
4. Davis P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 1403.
5. Dunnette SB, Low WC, Iversen SD, Stenevi U, Björklund A. Septal transplants restore maze learning in rats with fornixfimbria lesions. Brain Res 1982; 251: 335-348.
6. Cardozo MG, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. QSAR analysis of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 584-589.
7. Cardozo MG, Kawai T, Iimura Y, Sugimoto H, Yamanishi Y, Hopfinger AJ. Conformational analysis and molecular shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase. J Med Chem 1992; 35: 590-601.
8. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K. Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Biorg Med Chem Lett 1992; 2: 871-876.
9. Pang YP, Kozikowski AP. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J Comput Aided Mol Design 1994; 8: 683-693.
10. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase. Comparison with other inhibitors. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Volume 2, eds Nagatsu T, Fisher A, Yoshida M. New York: Plenum Press, 1990: 409-413.
11. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
12. Watkins PB, Zimmerman HJ, Knapp MJ et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-998.
13. Rogers SL, Friedhorff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
15. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open-label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
16. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
17. Lee JW, Rogers SL, Friedhoff, LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.
18. Hulse JD, Rogers SL, Friedhoff LT, Sukovaty R, Pedersen JE, Lee JW. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020). Pharm Res 1992; 9: S338.
19. Yamanishi Y, Ogura H, Kosasa T et al. Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats. Eur J Pharmacol 1990; 183: 1935.
20. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 7-12.
21. Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086-1091.
22. Mihara M, Ohnishi A, Tomono Y et al. Pharmacokinetics of E2020 a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993; 31: 223-229.